

Seth Baum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7756715/publications.pdf>

Version: 2024-02-01

57
papers

3,616
citations

361045
20
h-index

174990
52
g-index

60
all docs

60
docs citations

60
times ranked

3969
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2020, 382, 244-255.	13.9	559
2	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet</i> , 2019, 394, 2012-2024.	6.3	401
3	Clinical Genetic Testing for Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018, 72, 662-680.	1.2	387
4	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 850-861.	5.5	329
5	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1780.	3.8	314
6	Fatty acids in cardiovascular health and disease: A comprehensive update. <i>Journal of Clinical Lipidology</i> , 2012, 6, 216-234.	0.6	201
7	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , 2020, 41, 3936-3945.	1.0	188
8	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 240-249.	5.1	170
9	Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). <i>Nature Medicine</i> , 2022, 28, 96-103.	15.2	128
10	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	5.5	109
11	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	1.3	90
12	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 1401-1412.	1.0	78
13	PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017, 40, 243-254.	0.7	71
14	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017, 267, 19-26.	0.4	64
15	Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005404.	0.9	59
16	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1223-1229.	0.6	57
17	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. <i>The Lancet Digital Health</i> , 2019, 1, e393-e402.	5.9	49
18	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1234-1243.e5.	0.6	40

#	ARTICLE	IF	CITATIONS
19	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. Journal of the American College of Cardiology, 2019, 74, 1926-1942.	1.2	39
20	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. Circulation, 2017, 135, 2204-2206.	1.6	34
21	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq1 1 0.784314 rgBT19 Overlo	1.3	31
22	MR Imaging in the Definition of Coronary Artery Anomalies. Journal of Computer Assisted Tomography, 1990, 14, 171-174.	0.5	17
23	The doctor's dilemma: Challenges in the diagnosis and care of homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2014, 8, 542-549.	0.6	17
24	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 58.	0.4	16
25	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. Journal of Clinical Lipidology, 2022, 16, 617-625.	0.6	15
26	Statins and Diabetes. Cardiology Clinics, 2015, 33, 233-243.	0.9	14
27	Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. Journal of Clinical Lipidology, 2019, 13, 901-909.e3.	0.6	14
28	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiology, 2021, 17, 155-174.	0.5	14
29	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. American Journal of Preventive Cardiology, 2021, 8, 100278.	1.3	14
30	Rounding the corner on residual risk: Implications of REDUCEâ€™IT for omegaâ€™3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. Clinical Cardiology, 2019, 42, 829-838.	0.7	13
31	Statins and Diabetes. Endocrinology and Metabolism Clinics of North America, 2016, 45, 87-100.	1.2	12
32	Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. American Journal of Preventive Cardiology, 2021, 6, 100177.	1.3	11
33	PCSK9 inhibitor valuation: A scienceâ€™based review of the two recent models. Clinical Cardiology, 2018, 41, 544-550.	0.7	7
34	Acute Reversible Diffuse Conduction System Disease due to Lyme Disease. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 1367-1370.	0.5	6
35	ANCHOR Trial Conclusions Regarding the Effects of Pure Eicosapentaenoic Acid on Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2013, 111, 454-455.	0.7	6
36	Fatty Acids and Their Derivatives in Cardiovascular Disease: Arachidonic, Eicosapentaenoic, and Docosahexaenoic Acids and Their Byproducts, the Eicosanoids and Docosanoids. Current Cardiovascular Risk Reports, 2012, 6, 146-154.	0.8	5

#	ARTICLE	IF	CITATIONS
37	A Survey of Internists and Cardiologists: Are Discoveries in Fatty Acids Truly being translated into Clinical Practice?. Prostaglandins Leukotrienes and Essential Fatty Acids, 2013, 88, 3-4.	1.0	5
38	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. Postgraduate Medicine, 2016, 128, 31-39.	0.9	4
39	The American Society for Preventive Cardiology: Our 30-year legacy. Clinical Cardiology, 2016, 39, 627-630.	0.7	4
40	<p>Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified<p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1325-1332.	0.9	4
41	Evidence-Based Medicine: What's the Evidence?. Clinical Cardiology, 2012, 35, 259-260.	0.7	3
42	Accelerated atherosclerosis and elevated lipoprotein (a) after liver transplantation. Journal of Clinical Lipidology, 2016, 10, 434-437.	0.6	3
43	EPA and DHA: Distinct yet essential n-3 fatty acids. Journal of Clinical Lipidology, 2012, 6, 477.	0.6	2
44	Pitfalls of Population-Based Preventive Medicine. JAMA - Journal of the American Medical Association, 2013, 310, 2201.	3.8	2
45	A review of the evidence for alternative and complementary medical approaches in the prevention of atherosclerotic cardiovascular disease and diabetes. Cardiovascular Endocrinology, 2017, 6, 39-43.	0.8	2
46	CHARACTERISTICS OF PATIENTS APPROVED AND DENIED ACCESS TO PCSK9I THERAPY BY PAYERS. Journal of the American College of Cardiology, 2017, 69, 2534.	1.2	2
47	The 2017 high blood pressure clinical practice guideline: The old and the new. Clinical Cardiology, 2018, 41, 279-281.	0.7	2
48	Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia. Reviews in Cardiovascular Medicine, 2016, 17, 16-27.	0.5	2
49	From the "ivory Tower" to the trenches: A practical approach to the 2013 ACC/AHA Cholesterol and Risk Assessment Guidelines. Journal of Clinical Lipidology, 2014, 8, 231-233.	0.6	1
50	The American Society for Preventive Cardiology. Clinical Cardiology, 2018, 41, 709-709.	0.7	1
51	Dissecting lipid and lipoprotein issues in women: an in utero-through-menopause journey. Clinical Lipidology, 2015, 10, 431-448.	0.4	0
52	Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry. Journal of Clinical Lipidology, 2015, 9, 451-452.	0.6	0
53	The 2017 American Society for Preventive Cardiology Congress and Experts Course. Clinical Cardiology, 2017, 40, 520-520.	0.7	0
54	Cardiovascular disease prevention in the health economics era: Clinicians need more than just prescription pads. American Journal of Preventive Cardiology, 2020, 1, 100004.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Rethinking our Guideline System: Returning to Evidence Based Medicine as it was Originally Intended. Journal of Hypertension and Management, 2016, 2, .	0.1	0
56	Access to PCSK9 Inhibitors. Reviews in Cardiovascular Medicine, 2018, 19, 47-50.	0.5	0
57	Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag. Reviews in Cardiovascular Medicine, 2018, 19, 25-30.	0.5	0